about
Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in KoreaDocetaxel versus paclitaxel combined with 5-FU and leucovorin in advanced gastric cancer: combined analysis of two phase II trialsSalvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer.Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patientsPrognostic implications of PD-L1 expression in patients with soft tissue sarcoma.Rho GTPase RhoJ is Associated with Gastric Cancer Progression and Metastasis.Prognosis of pN3 stage gastric cancer.Clinical value of ezrin expression in primary osteosarcoma.Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer.Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma.PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.The Clinicopathologic Features and Prognostic Impact of ALK Positivity in Patients with Resected Gastric Cancer.Phase II gemcitabine and capecitabine combination therapy in recurrent or metastatic breast cancer patients pretreated with anthracycline and taxanePredictive Nomogram for Recurrence of Stage I Colorectal Cancer After Curative ResectionMET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasisThe clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancerTumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint BlockadeSTING signaling is a potential immunotherapeutic target in colorectal cancerSTING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockadeRandomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer
P50
Q33385981-831DFCE8-7023-467D-A4B5-503CD7606B17Q33576276-33E1E3AD-CC50-47ED-9073-065769DEA2A7Q35233550-DBC7976B-CA30-4D63-AC07-21E6E8C4DDAAQ36067835-49A95C9A-CD9A-4120-A22C-E1A0A4FD798CQ36072022-DDDF9145-A44E-4A60-B897-416436DA83D3Q37133691-C6946909-187C-43CF-9416-D73BF586EAECQ37316735-9F52AB1C-4F5E-4575-99F5-CA16AF2573B3Q37376890-7AD1948A-E196-4505-AC84-F3F3048C01BAQ38406050-3628C2D6-3763-4976-A93E-A012BB313FF8Q40320758-6DAC7A18-6996-48E2-91D2-D08FF7A192F2Q47838777-C477CF7F-B97B-4506-B356-B52B62AF3D53Q53607051-AF1C843B-E8F7-4113-BB47-6DC487A1423AQ57222268-D64B54A5-7C8C-4D5E-8875-782A24C9D8F8Q88375781-BD1324A3-12AE-47CF-B3B7-30B1D5AFC1CFQ88780568-051A444B-EAB9-4F56-8A37-0FC609B914ABQ89285151-E80535C9-6C03-44CC-A44A-8747E0C13237Q90410945-04018DDC-6DCA-49F3-B261-3FFEA92362E1Q90618686-ABED3C19-0AB6-454E-989A-23F066D72BA5Q92172123-7AC4DA69-1E32-41AA-8919-75F88DFF56DCQ92555974-3396BAA0-8ABE-4E5D-9ED1-9B1D91127D64
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Hong Jae Chon
@en
Hong Jae Chon
@nl
type
label
Hong Jae Chon
@en
Hong Jae Chon
@nl
prefLabel
Hong Jae Chon
@en
Hong Jae Chon
@nl
P31
P496
0000-0002-6979-5812